Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology
G Grazia(Breast Cancer Research Foundation), F. Schettini(Breast Cancer Research Foundation), Paolo Vigneri(Humanitas University), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Casals-Pascual Climent(Instituto de Salud Carlos III), A. Prat(Cancer Clinic), Tomás Pascual(Cancer Clinic), Javier Cortés(MedSIR (Spain)), Nadia Harbeck(Ludwig-Maximilians-Universität München), Daniele Generali(University of Trieste)
Cited by 6
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282